Retatrutide 20 mg is the mid-range lyophilised vial supplied by BuyRetaUK — the default choice for routine multi-well and multi-plate in-vitro experimentation, balancing per-milligram economics against manageable aliquot count and freeze-thaw exposure.
Retatrutide 20 mg is a 20-milligram lyophilised research-peptide vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the mid-range presentation in the BuyRetaUK Retatrutide ladder, chosen when routine multi-well or multi-plate assays need more mass than a 10 mg vial provides.
Retatrutide 20 mg is a lyophilised vial containing 20 milligrams of Retatrutide (LY3437943), a triple GLP-1 / GIP / glucagon receptor agonist under active research investigation. In the BuyRetaUK ladder it is the mid-range presentation and the default working vial for laboratories whose routine studies consume more peptide than a single 10 mg vial can serve.
For compound-level background, receptor pharmacology and study context, see the cornerstone What is Retatrutide? guide.
A step down to Retatrutide 10 mg makes sense for shorter or lower-consumption protocols; a step up to Retatrutide 30 mg fits extended runs where standardising a single larger reconstitution volume simplifies workflow. All three share the same release specification — the choice is one of study scope, not quality. Compare side-by-side in the Strengths Hub.
Every vial ships with a batch-specific COA · UK dispatch
The 20 mg vial carries a batch-specific Certificate of Analysis identical in structure to those for the 10, 30 and 40 mg presentations. Every batch resolves to a unique batch number cross-referenced in the verification library. Field-by-field interpretation lives in the Certificate of Analysis guide.
20 mg vials are released against a ≥99% HPLC-UV area-percent specification with ESI-MS identity confirmation. Method context, impurity profiling and interpretation guidance live in the Retatrutide Purity reference.
20 mg vials should be held at 2–8 °C short-term and at −20 °C for extended holding. With a 20 mg reconstitution, aliquot planning matters — divide into single-use portions immediately after reconstitution to minimise freeze-thaw exposure. See the Retatrutide Storage guide for the full framework.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →A 20 mg reconstitution typically produces 4–20 useful aliquots; plan the portioning grid before opening the vial.
Choose a standard diluent volume so every 20 mg vial produces the same working concentration across studies.
Compare 20 mg per-mg pricing against 10, 30 and 40 mg on the product page before scaling up.
Cross-check the batch label against the published Certificate of Analysis before reconstituting.
20 mg gives a laboratory enough peptide mass to run routine multi-well and multi-plate work from a single reconstitution, while keeping aliquot count and freezer footprint manageable. It is the mid-range balance point in the 10–40 mg ladder.
Reconstituting 20 mg in 2 mL of bacteriostatic water yields 10 mg/mL; in 4 mL yields 5 mg/mL; in 10 mL yields 2 mg/mL. Use the reconstitution calculator to target any working concentration.
Move to 30 mg when a single reconstitution needs to serve a longer or larger run — for example, when 20 mg would require repeat vial opens or when standardising a fixed reconstitution volume across several experiments.
No. The 10, 20, 30 and 40 mg vials are all released against the same ≥99% HPLC-UV purity and mass-spectrometric identity specification. Only the packaged mass differs.
Absolute price scales sub-linearly with vial strength — a 20 mg vial typically offers better per-milligram economics than a 10 mg vial at the same purity. Full per-strength pricing lives on the product page.
No. Every BuyRetaUK Retatrutide vial, including 20 mg, is supplied for in-vitro laboratory research only and is not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Compound overview, receptor profile and research framing.
Triple vs dual incretin agonist — how they differ.
Triple agonist vs single GLP-1 agonist.
How to verify identity, purity and batch quality.
Every retatrutide variant with lab data.
Solvent volume and dose-per-unit calculator.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Storage & HandlingHow to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Retatrutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →Lyophilised vials are stored at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days.
Read: What is Retatrutide? →
